Digital Content

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. We’ll assume you’re ok with this, but you can opt out if you wish. See our 

Footer

Column Name Goes Here

Footer V2

2024 Event

Event Global

New HLTH Insights Programs

Become a Hosted Buyer

Become a Sponsor/Exhibitor

Apply for Media Pass

Promote Your Presence

2023 Event

Event Global Footer

Startup Opportunities

Hotel

2022 Event

LLC Global

2021 Event

LLC Menu Official

LLC Menu

AI @ HLTH: Harnessing AI for Diabetic Retinopathy

In this episode, host Sandy Vance chats with <a href="https://www.optomed.com/us/" target="_blank" style="font-size: 16px;">Optomed</a> Managing Director <a href="https://www.linkedin.com/in/david-frasch-6a944644" target="_blank" style="font-size: 16px;">David Frasch</a> about how AI can augment physicians&#39; abilities and daily responsibilities in this space. Optomed is a handheld fundus camera manufacturer based in Finland and has been in operation for the last 20 years. Listen as David sheds light on how Optomed cameras harness the power of AI to enhance the diagnosis and management of diabetic retinopathy. They explore the development of cutting-edge algorithms for medical diagnostics, the challenges of creating clinical algorithms without standardization, and the broad applications of AI across the healthcare sector. Stay tuned for a fascinating discussion on the transformative impact of AI in healthcare! A Little About David:With a decade of experience in medical sales within ophthalmology, David has recently excelled in building high-performance sales teams at BioTissue. As a director there, he successfully transformed the team&#39;s performance from worst to first, a process that was both challenging and rewarding. In his new role at Optomed, David aims to replicate this success by focusing on team development and growth. He is committed to growing the team in a controlled manner and laying a strong foundation for building a powerful and resilient organization. In this episode, they talk about:<ul><li>How Optomed leverages AI to improve diagnosis and treatment of diabetic retinopathy</li><li>Developing advanced algorithms for medical diagnostics</li><li>Challenges in creating optimal clinical algorithms without standardization</li><li>Applications of AI across various sectors in the healthcare industry</li><li>Addressing ethical and privacy concerns in AI-driven healthcare solutions</li><li>Emerging trends in the application of AI in medicine and healthcare</li><li>The strategic partnership between AI Health and Optomed</li><li>Future collaborative opportunities between AI Health and physicians</li></ul>

Managing Director

Bringing Real Health Equity for Healthier Lives—featuring Andrew Toy and Carlade

Health equity starts with human equity. In this episode, Andrew Toy, President and incoming CEO at Clover Health, and Carladenise Armbrister Edwards, Executive Vice President and Chief Strategy Officer at Henry Ford Health and board member at Clover Health, talk about finding technology solutions and personalized approaches that bring accurate health equity, enabling people to live longer, healthier, happier lives. Clover Health is a company that uses a distributed care model focused on the Medicare Advantage population, using its resources on the people who need it, when, where, and how they need it. Andrew and Carladenise discuss the responsibility that is health equity and why barriers like misaligned structures, incentives, and values have made it a hard-to-achieve goal. They also speak about how being aware of the problem at hand and committing to kindness and justness can be the starting point to building health equity. Learn more about Clover Health’s distributed care model and its leaders’ take on health equity!  About Andrew Toy:Andrew Toy is the President at Clover Health, where he is responsible for driving the vision for how technology and analytics can improve the lives of Clover&#39;s members. Andrew joined Clover from Google, where he coordinated enterprise activities for the Android team and ran Machine Learning, Enterprise Search, and Analytics for the G-Suite team. Before that, he was the CEO and co-founder of Divide, a company focused on creating a split between work and personal data on mobile devices, which was acquired by Google in 2014. He earned his BS and MS in Computer Science from Stanford University. About Carladenise Armbrister Edwards:Dr. Carladenise Armbrister Edwards has served as the Chief Strategy Officer at Henry Ford Health, a $6B private non-profit system in Southeast Michigan; Providence, a $26B Catholic healthcare system with over 50 hospitals across seven Western states; and Alameda Health System, a public hospital authority located in Oakland, California. As the principal advisor to the CEO and executive team, she has led system-wide strategic planning, M&amp;A, and other partnership ventures, business development, clinical and operational transformation initiatives, government affairs, marketing, and communications, population health, and managed care contracting. Dr. Edwards also served as Founding President and CEO of Cal eConnect, Inc., a nonprofit corporation that governed California&#39;s electronic Health Information Exchange. Additionally, she has held executive leadership roles in Georgia&#39;s Department of Community Health, Florida’s Agency for Healthcare Administration, and the US Department of Health and Human Services. Dr. Edwards joined Clover Health’s Board of Directors in July 2022. Dr. Edwards holds a Ph.D. in Medical Sociology from the University of Florida, a master&#39;s degree in Education and Psychological Services, and a bachelor&#39;s degree in Sociology from the University of Pennsylvania. Things You’ll Learn:<ul><li>Medicare Advantage is the perfect example of how to provide health equity, as it gives money and resources to prevent illness and treat illness in a personalized manner.</li><li>Decentralizing care can make clinicians more efficient and help them perform at the top of their license with the help of technology and analytics.</li><li>The current hospital experience could be more efficient and scary, but it can be fixed using different tools and models of care.</li><li>Organizations like Clover must ensure everybody gets access to the care they need, taking into account their social, economic, and environmental factors.</li><li>Structural barriers, such as the structure of insurance and societal values, often create a disincentive to providing care to those who need it most.</li><li>Everyone can be part of health equity by taking care of themselves first.</li><li>Hospitals should be places where we go for certain aspects of our healthcare, not all of them. </li></ul> Resources:<ul><li>Connect with and follow Andrew Toy on LinkedIn.</li><li>Connect with and follow Carladenise Armbrister Edwards on LinkedIn.</li><li>Follow Clover Health on LinkedIn.</li><li>Visit the Clover Health Website!</li></ul>

S3 Ep46: Bringing Real Health Equity for Healthier Lives—featuring Andrew Toy and Carladenise Edwards

President

EVP and Chief Strategy Officer

AI @ HLTH: The Future of Healthcare Training: ReflexAI's AI Innovations Unveiled

In this episode of The Beat, Sandy Vance sits down with Sam Dorison, Co-Founder and CEO of ReflexAI, to explore the transformative role of AI technology in healthcare. From its origins at the Trevor Project to its groundbreaking applications today, ReflexAI is revolutionizing patient care through advanced AI-driven simulations. Join us as Sam delves into how ReflexAI’s innovative solutions are addressing critical challenges in the healthcare industry, enhancing patient support, and improving training environments. Discover the impact of ReflexAI’s technology and get an insider’s look at how it’s shaping the future of healthcare. ReflexAI helps maximize training and quality assurance platforms using AI in order to help cut costs and increase efficiency. You can email questions and reach out to Sam at <a href="mailto:contact@reflexai.com" target="_blank" style="font-size: 16px; color: rgb(17, 85, 204); background-color: transparent;">contact@reflexai.com</a>.  A Little About Sam:Sam Dorison is the Cofounder and Chief Executive Officer at ReflexAI. An expert in artificial intelligence strategy and product deployment, Dorison has been involved with AI-powered products in industries ranging from mental health to cybersecurity to smart cities. Before launching ReflexAI, he served as Chief Strategy &amp; Innovation Officer at The Trevor Project, the world’s largest suicide prevention and crisis intervention organization for LGBTQ young people. There, he published five peer-reviewed articles on mental health and oversaw teams including crisis services, training, research, technology, and finance. Dorison previously worked at McKinsey &amp; Company and Harvard Kennedy School. He graduated summa cum laude and Phi Beta Kappa from Princeton University’s School of Public and International Affairs. He also holds an LL.M. from Cambridge University and a master’s degree from University College London, both as a Marshall Scholar. Beyond ReflexAI, Dorison is heavily involved in causes that support families impacted by cancer. Dorison lives in New York City with his husband. In this episode, they talk about:<ul><li>The evolution of ReflexAI from its inception at the Trevor Project.</li><li>How ReflexAI leverages AI technology to tackle challenges in the healthcare industry.</li><li>Creating Healthcare Flight Simulator for front line clinicians</li><li>Specific use cases where ReflexAI’s AI-driven simulations have been particularly impactful in healthcare settings.</li><li>How ReflexAI’s AI-driven simulations enhance patient support and training across various healthcare environments.</li><li>An overview of the mechanics behind ReflexAI and its impact on improving patient care.</li></ul>

Co-Founder and Chief Executive Officer

A New Dawn in Early Cancer Detection with Dr. Megan Hall of GRAIL

In this groundbreaking era of healthcare, the opportunity to revolutionize cancer outcomes has never been more promising. With cutting-edge testing techniques, early detection strategies, and the power of AI, the landscape of cancer care is evolving to save lives and enhance patient well-being like never before. In this episode of HLTH Matters, Dr. Gautam Gulati sits down with Dr. Megan Hall to discuss the future of cancer detection and prevention through early genetic testing.  <a href="https://www.linkedin.com/in/megan-p-hall-2401068/" target="_blank">Dr. Megan Hall</a> is the Vice President of Corporate Affairs at <a href="https://grail.com/" target="_blank">GRAIL</a>. With a Ph.D. in microbiology, immunology, and molecular genetics she is dedicated to making early cancer detection and prevention accessible on a population scale. As Dr. Hall says, “I was enamored of the mission to detect cancer early when it can be cured. That&#39;s a huge problem that we have to be frank have not made great headway on in the 50 years that we&#39;ve been waging this war on cancer.”  Now she shares how GRAIL&#39;s flagship product, <a href="https://grail.com/galleri-test/" target="_blank">Galleri</a>, is using advanced technology, including DNA methylation analysis and artificial intelligence (AI), to detect and predict cancer in a non-invasive way.  Listen in as we explore the potential cost savings and improved outcomes with early cancer detection, and GRAIL&#39;s efforts to make this transformative technology accessible to a broader population.  Topics Covered<ul><li>The significance of early detection in cancer care</li><li>The role of DNA methylation in cancer detection</li><li>The importance of evaluating the accuracy of cancer screening and the power of positive predictive value</li><li>The need for education across the cancer care continuum</li><li>The potential for healthcare cost savings with early cancer detection</li><li>The role of AI and machine learning in cancer detection</li><li>GRAIL&#39;s focus on expanding access to cancer screening and its plans for future products</li></ul>Connect with Dr. Megan Hall<ul><li>Dr. Hall on <a href="https://www.linkedin.com/in/megan-p-hall-2401068/" target="_blank">LinkedIn</a> </li></ul>Connect with Dr. Gautam Gulati &amp; Dr. Jessica Shepherd <ul><li><a href="https://www.hlth.com/" target="_blank">HLTH</a></li><li>Dr. Gulati on <a href="https://twitter.com/drgautamgulati" target="_blank">X</a> </li><li>Dr. Gulati on <a href="https://www.linkedin.com/in/gautamgulati" target="_blank">LinkedIn</a></li><li><a href="https://www.drjessicashepherd.com/about" target="_blank">Dr. Jessica Shepherd MD </a></li><li>Dr. Shepherd on <a href="https://twitter.com/JShepherd_MD" target="_blank">X</a> </li></ul>Resources <ul><li><a href="https://grail.com/" target="_blank">GRAIL</a> </li><li><a href="https://grail.com/galleri-test/" target="_blank">Galleri Test - GRAIL </a></li></ul>

S4 E41: A New Dawn in Early Cancer Detection with Dr. Megan Hall of GRAIL

Head of Corporate Affairs, Distinguished Scientist

Podcast

AI @ HLTH: Harnessing AI for Diabetic Retinopathy

FEATURING